Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men
Open Access
- 1 March 2008
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (3), 914-919
- https://doi.org/10.1210/jc.2007-1692
Abstract
Context: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men. Objective: Our objective was to compare the dose-related changes in hemoglobin and hematocrit in young and older men and determine whether age-related differences in erythropoietic response to testosterone can be explained by changes in erythropoietin and soluble transferrin receptor (sTfR) levels. Design: We conducted a secondary analysis of data from a testosterone dose-response study in young and older men who received long-acting GnRH agonist monthly plus one of five weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 wk. Setting: The study took place at a General Clinical Research Center. Participants: Participants included 60 older men aged 60–75 yr and 61 young men aged 19–35 yr. Outcome Measures: Outcome measures included hematocrit and hemoglobin and serum erythropoietin and sTfR levels. Results: Hemoglobin and hematocrit increased significantly in a linear, dose-dependent fashion in both young and older men in response to graded doses of testosterone (P < 0.0001). The increases in hemoglobin and hematocrit were significantly greater in older than young men. There was no significant difference in percent change from baseline in erythropoietin or sTfR levels across groups in either young or older men. Changes in erythropoietin or sTfR levels were not significantly correlated with changes in total or free testosterone levels. Conclusions: Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.Keywords
This publication has 34 references indexed in Scilit:
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaThe New England Journal of Medicine, 2006
- Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2006
- Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingNature Clinical Practice Endocrinology & Metabolism, 2006
- Influence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasmaJournal of Endocrinology, 2005
- Androgen and Erythropoiesis: Evidence for an Androgen Receptor in Erythroblasts from Human Bone Marrow CulturesHormone Research, 1988
- Androgen therapy in haemodialysis patients..British Journal of Haematology, 1987
- Clinical Applications of Measurement of Serum Immunoreactive Levels of ErythropoietinAnnals of the New York Academy of Sciences, 1985
- THE MECHANISM OF ACTION OF ANDROGENS ON ERYTHROPOIESISAnnals of the New York Academy of Sciences, 1968
- Testosterone-Induced Remission in Aplastic Anemia of Both Acquired and Congenital TypesThe New England Journal of Medicine, 1961